Physician profile
Javed Ahmad
NPI 1346354479
$2,507.99
in general payments reported to CMS, 2019-2025
29 companies · $148 in 2025
The $148 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $671 · 2020: $196 · 2021: $418 · 2022: $94.99 · 2023: $556 · 2024: $425 · 2025: $148.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,129.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,129.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $582.09 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $233.34 | 2023-2024 | Ubrelvy, Qulipta, Linzess |
| Astellas Pharma US INC | $168.71 | 2019-2021 | |
| Glaxosmithkline, LLC. | $165.83 | 2019-2024 | Trelegy Ellipta, Arexvy |
| Janssen Pharmaceuticals, INC | $159.07 | 2019-2024 | Xarelto |
| Sanofi-Aventis U.S. LLC | $119.50 | 2019 | |
| Pfizer INC. | $109.84 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $107.13 | 2019-2025 | Farxiga, Breztri |
| Sumitomo Pharma America, INC. | $103.75 | 2023-2024 | Gemtesa |
| Amgen INC. | $86.98 | 2019-2024 | Repatha, Otezla |
| Xeris Pharmaceuticals, INC. | $77.94 | 2021-2025 | Gvoke Hypopen |
| Lilly USA, LLC | $70.73 | 2023-2024 | Jardiance, Emgality |
| Philips North America LLC | $68.22 | 2019-2024 | (8874) Incourage |
| Boehringer Ingelheim Pharmaceuticals, INC. | $61.28 | 2024-2025 | Tradjenta, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $57.14 | 2021-2024 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $52.22 | 2019-2022 | |
| Amarin Pharma, INC. | $38.16 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $30.45 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $29.01 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Cmp Pharma, INC. | $25.67 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $23.87 | 2025 | Rexulti |
| Biogen, INC. | $22.65 | 2021 | |
| Vifor Pharma, INC. | $21.86 | 2019 | |
| Medtronic, INC. | $19.39 | 2024 | Minimed 780g |
| Cook Medical LLC | $15.65 | 2024 | Zilver Ptx |
| Dexcom, INC. | $15.00 | 2019 | |
| Ironwood Pharmaceuticals, INC | $14.46 | 2023 | Linzess |
| Viatris Specialty LLC | $14.06 | 2025 | Yupelri |
| E.R. Squibb & Sons, L.L.C. | $13.99 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Javed Ahmad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.